Pfizer achieved positive results from the ORAL Scan Phase III study of tofacitinib, an investigational oral JAK inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX). Patients were randomized to receive tofacitinib 5 or 10 mg BID or placebo added to background MTX. The study met all primary endpoints at the 10 mg BID dose, showing statistically significant changes versus placebo in reducing signs and symptoms of R...